Last reviewed · How we verify
Atazanavir + saquinavir + tenofovir + nucleoside
Atazanavir + saquinavir + tenofovir + nucleoside is a Antiretroviral combination (protease inhibitors + nucleotide reverse transcriptase inhibitor) Small molecule drug developed by Bristol-Myers Squibb. It is currently in Phase 3 development for HIV-1 infection. Also known as: BMS-232632, Reyataz.
This combination inhibits HIV protease and reverse transcriptase to suppress viral replication.
This combination inhibits HIV protease and reverse transcriptase to suppress viral replication. Used for HIV-1 infection.
At a glance
| Generic name | Atazanavir + saquinavir + tenofovir + nucleoside |
|---|---|
| Also known as | BMS-232632, Reyataz |
| Sponsor | Bristol-Myers Squibb |
| Drug class | Antiretroviral combination (protease inhibitors + nucleotide reverse transcriptase inhibitor) |
| Target | HIV protease, HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 3 |
Mechanism of action
Atazanavir and saquinavir are protease inhibitors that block HIV protease, preventing the maturation of infectious viral particles. Tenofovir is a nucleotide reverse transcriptase inhibitor that blocks HIV reverse transcriptase, preventing conversion of viral RNA to DNA. Together, these agents target multiple steps of the HIV replication cycle to reduce viral load.
Approved indications
- HIV-1 infection
Common side effects
- Diarrhea
- Nausea
- Hyperbilirubinemia
- Headache
- Rash
- Nephrolithiasis
- Renal dysfunction
Key clinical trials
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants (PHASE3)
- Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I (PHASE3)
- Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years (PHASE3)
- Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults (PHASE3)
- Interaction With HIV Antiretroviral Agents (PHASE1)
- Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients (PHASE3)
- Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atazanavir + saquinavir + tenofovir + nucleoside CI brief — competitive landscape report
- Atazanavir + saquinavir + tenofovir + nucleoside updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI
Frequently asked questions about Atazanavir + saquinavir + tenofovir + nucleoside
What is Atazanavir + saquinavir + tenofovir + nucleoside?
Atazanavir + saquinavir + tenofovir + nucleoside is a Antiretroviral combination (protease inhibitors + nucleotide reverse transcriptase inhibitor) drug developed by Bristol-Myers Squibb, indicated for HIV-1 infection.
How does Atazanavir + saquinavir + tenofovir + nucleoside work?
This combination inhibits HIV protease and reverse transcriptase to suppress viral replication.
What is Atazanavir + saquinavir + tenofovir + nucleoside used for?
Atazanavir + saquinavir + tenofovir + nucleoside is indicated for HIV-1 infection.
Who makes Atazanavir + saquinavir + tenofovir + nucleoside?
Atazanavir + saquinavir + tenofovir + nucleoside is developed by Bristol-Myers Squibb (see full Bristol-Myers Squibb pipeline at /company/bristol-myers-squibb).
Is Atazanavir + saquinavir + tenofovir + nucleoside also known as anything else?
Atazanavir + saquinavir + tenofovir + nucleoside is also known as BMS-232632, Reyataz.
What drug class is Atazanavir + saquinavir + tenofovir + nucleoside in?
Atazanavir + saquinavir + tenofovir + nucleoside belongs to the Antiretroviral combination (protease inhibitors + nucleotide reverse transcriptase inhibitor) class. See all Antiretroviral combination (protease inhibitors + nucleotide reverse transcriptase inhibitor) drugs at /class/antiretroviral-combination-protease-inhibitors-nucleotide-reverse-transcriptase-inhibitor.
What development phase is Atazanavir + saquinavir + tenofovir + nucleoside in?
Atazanavir + saquinavir + tenofovir + nucleoside is in Phase 3.
What are the side effects of Atazanavir + saquinavir + tenofovir + nucleoside?
Common side effects of Atazanavir + saquinavir + tenofovir + nucleoside include Diarrhea, Nausea, Hyperbilirubinemia, Headache, Rash, Nephrolithiasis.
What does Atazanavir + saquinavir + tenofovir + nucleoside target?
Atazanavir + saquinavir + tenofovir + nucleoside targets HIV protease, HIV reverse transcriptase and is a Antiretroviral combination (protease inhibitors + nucleotide reverse transcriptase inhibitor).
Related
- Drug class: All Antiretroviral combination (protease inhibitors + nucleotide reverse transcriptase inhibitor) drugs
- Target: All drugs targeting HIV protease, HIV reverse transcriptase
- Manufacturer: Bristol-Myers Squibb — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for HIV-1 infection
- Also known as: BMS-232632, Reyataz
- Compare: Atazanavir + saquinavir + tenofovir + nucleoside vs similar drugs
- Pricing: Atazanavir + saquinavir + tenofovir + nucleoside cost, discount & access